➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

McKinsey
Merck
Mallinckrodt
Harvard Business School
Baxter
McKesson

Last Updated: September 27, 2020

DrugPatentWatch Database Preview

Claims for Patent: 8,426,585

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Summary for Patent: 8,426,585
Title:Compounds comprising a spiro-ring
Abstract: The present invention provides novel compounds useful in modulating the protein tyrosine kinase activity, and in modulating inter- and/or intra-cellular signaling. The invention also provides pharmaceutically acceptable compositions comprising such compounds and methods of using the compositions in the treatment of hyperproliferative disorders in mammals, especially humans.
Inventor(s): Xi; Ning (Newbury Park, CA)
Assignee: Xi; Ning (Newbury Park, CA) Sunshine Lake Pharma Co., Ltd. (Northern Industrial Area, Songshan Lake, Dongguan, Guangdong, CN)
Application Number:13/587,936
Patent Claims:1. A compound of Formula (I): ##STR00081## or a stereoisomer, a geometric isomer, a tautomer, an N-oxide, or a pharmaceutically acceptable salt thereof, wherein: Q.sub.1 is formula (IIa): ##STR00082## Q.sub.2 is formula (III): ##STR00083## R.sup.1 is hydroxy-substituted cyclopropylalkoxy, R.sup.5S(.dbd.O).sub.2O-substituted cyclopropylalkoxy, spiro bicyclyl, spiro heterobicyclyl, spiro bicyclyl aliphatic, spiro heterobicyclyl aliphatic, spiro bicycloxy, spiro heterobicyclylamino, spiro bicycloxoalkoxy, spiro heterobicycloxoalkoxy, spiro bicyclylaminoalkoxy, spiro heterobicyclylaminoalkoxy, spiro bicyclyl --C(.dbd.O)--, spiro bicyclyl-C(.dbd.O)O--, spiro heterobicyclyl-C(.dbd.O)--, spiro heterobicyclyl-C(.dbd.O)O--, spiro bicyclylamino-C(.dbd.O)--, spiro heterobicyclylamino-C(.dbd.O)--, spiro bicyclyl-C(.dbd.O)NR.sup.5--, or spiro heterobicyclyl-C(.dbd.O)NR.sup.5--, or R.sup.1 has one of the following structures: ##STR00084## ##STR00085## ##STR00086## wherein each of X.sub.4 and X.sub.4' is independently (CR.sup.4R.sup.4a).sub.m, NR.sup.5, O, S, S.dbd.O or SO.sub.2; each of m and n is independently 0, 1 or 2; and t is 1, 2 or 3; R.sup.2 is H, halo, cyano, hydroxyl, R.sup.5aR.sup.5N--, --C(.dbd.O)NR.sup.5R.sup.5a, --OC(.dbd.O)NR.sup.5R.sup.5a, --OC(.dbd.O)OR.sup.5, --NR.sup.5C(.dbd.O)NR.sup.5R.sup.5a, --NR.sup.5C(.dbd.O)OR.sup.5a, --NR.sup.5C(.dbd.O)--R.sup.5a, R.sup.5R.sup.5aN--O.sub.2S--, R.sup.5O.sub.2S--, R.sup.5O.sub.2SR.sup.5aN--, R.sup.5aR.sup.5N-alkyl, R.sup.5(S.dbd.O)-alkyl, R.sup.5R.sup.5aN-(C.dbd.O)alkyl, R.sup.5aR.sup.5N-alkoxy, R.sup.5(S.dbd.O)-alkoxy, R.sup.5R.sup.5aN-(C.dbd.O)-alkoxy, aliphatic, alkoxy, hydroxyalkoxy, aminoalkoxy, hydroxy-substituted aminoalkoxy, haloalkoxy, amino-substituted haloalkoxy, alkylamino haloalkoxy, hydroxy-substituted haloalkoxy, alkylaminoalkoxy, alkoxyalkoxy, arylalkoxy, heterocyclylalkoxy, carbocyclylalkoxy, heterocyclyl(hydroxyalkoxy), carbocyclyl(hydroxyalkoxy), aryl(hydroxyalkoxy), aryloxyalkoxy, aryloxy, heterocyclyloxyalkoxy, carbocyclyloxyalkoxy, heterocyclyloxy, cycloalkyloxy, (heterocyclo)hydroxyalkoxy, azidoalkoxy, fused bicyclyl, fused heterobicyclyl, fused bicyclyl aliphatic, fused heterobicyclyl aliphatic, fused bicycloxy, fused heterobicycloxy, fused bicyclylamino, fused heterobicyclylamino, fused bicycloxoalkoxy, fused heterobicycloxoalkoxy, fused bicyclyl aminoalkoxy, fused heterobicyclyl aminoalkoxy, fused bicyclyl-C(.dbd.O)--, fused bicyclyl-C(.dbd.O)O--, fused heterobicyclyl-C(.dbd.O)--, fused heterobicyclyl-C(.dbd.O)O--, fused bicyclylamino-C(.dbd.O)--, fused heterobicyclylamino-C(.dbd.O)--, fused bicyclyl-C(.dbd.O)NR.sup.5--, fused heterobicyclyl-C(.dbd.O)NR.sup.5--, spiro bicyclyl, spiro heterobicyclyl, spiro bicyclyl aliphatic, spiro heterobicyclyl aliphatic, spiro bicycloxy, spiro heterobicycloxy, spiro bicyclylamino, spiro heterobicyclylamino, spiro bicycloxoalkoxy, spiro heterobicycloxoalkoxy, spiro bicyclylaminoalkoxy, spiro heterobicyclylaminoalkoxy, spiro bicyclyl --C(.dbd.O)--, spiro bicyclyl-C(.dbd.O)O--, spiro heterobicyclyl-C(.dbd.O)--, spiro heterobicyclyl-C(.dbd.O)O--, spiro bicyclylamino-C(.dbd.O)--, spiro heterobicyclylamino-C(.dbd.O)--, spiro bicyclyl-C(.dbd.O)NR.sup.5--, or spiro heterobicyclyl-C(.dbd.O)NR.sup.5--, aryl, heteroaryl, arylaliphatic or heteroarylaliphatic, with the proviso that when alkoxy or alkylamino is substituted, each of alkoxy or alkylamino is independently substituted with one or more hydroxy groups, amino groups or substituted amino groups; R.sup.3 is H, F, Cl, Br, I, --CN, hydroxyl, R.sup.5aR.sup.5N--, aliphatic, alkoxy, haloalkyl, heterocyclyl, heterocyclylalkyl, cycloalkyl, cycloalkyl aliphatic, cycloalkylalkoxy, or heterocyclylalkoxy; each of U.sub.1 and U.sub.2 is independently CR.sup.4 or N; V.sub.1 is O or NR.sup.5; V.sub.2 is cR.sup.4R.sup.4a, NRS, CR.sup.4 or N, and V.sub.3 and V.sub.4 combine to become CR.sup.4R.sup.4a, NR.sup.5, O, CR.sup.4 or N; each of W.sub.1, W.sub.2, W.sub.3 and W.sub.4 is independently CR.sup.4R.sup.4a, NR.sup.5, CR.sup.4 or N; X.sub.1 is (CR.sup.4R.sup.4a).sub.m, NR.sup.5, O, S, S.dbd.O or SO.sub.2, where m is 0, 1 or 2; X.sub.2 is O, S or NR.sup.5; Z is --NR.sup.5C(.dbd.O)--(CR.sup.4R.sup.4a).sub.p--, --NR.sup.5C(.dbd.S)--(CR.sup.4R.sup.4a).sub.p--, --NR.sup.5a--(CR.sup.4R.sup.4a).sub.p--, --NR.sup.5--(CR.sup.4R.sup.4a).sub.pC(.dbd.O)--, --NR.sup.5--(CR.sup.4R.sup.4a).sub.pC(.dbd.S)--, --NR.sup.5S(.dbd.O).sub.r--, --NR.sup.5S(.dbd.O).sub.r(CR.sup.4R.sup.4a).sub.p--, --C(.dbd.O)NR.sup.5(CR.sup.4R.sup.4a).sub.p-- or --NR.sup.5--(CR.sup.4R.sup.4a).sub.nS(.dbd.O).sub.r--, where p is 0, 1, 2 or 3 and r is 1 or 2; each of R.sup.4 and R.sup.4a is independently H, F, Cl, Br, I, --CN, hydroxyl, --NR.sup.5aR.sup.5, alkoxy, cycloalkoxy, heterocycloalkoxy, aliphatic, haloaliphatic, hydroxyaliphatic, aminoaliphatic, alkoxyaliphatic, alkylaminoaliphatic, alkylthioaliphatic, arylaliphatic, heterocyclylaliphatic, cycloalkylaliphatic, aryloxyaliphatic, heterocyclyloxyaliphatic, cycloalkyloxyaliphatic, arylaminoaliphatic, heterocyclylaminoaliphatic, cycloalkylaminoaliphatic, aryl, heteroaryl, heterocyclyl or carbocyclyl, with the proviso that where R.sup.4 and R.sup.4a are bonded to the same carbon atom, R.sup.4 and R.sup.4a, together with the carbon atom they are attached to, optionally form a substituted or unsubstituted 3-8 membered carbocyclic or heterocyclic ring; each of R.sup.5 and R.sup.5a is independently H, R.sup.6R.sup.6aNC(.dbd.O)--, R.sup.6OC(.dbd.O)--, R.sup.6C(.dbd.O)--, R.sup.6R.sup.6aNS(.dbd.O)--, R.sup.6OS(.dbd.O)--, R.sup.6S(.dbd.O)--, R.sup.6R.sup.6aNSO.sub.2--, R.sup.6OSO.sub.2--, R.sup.6SO.sub.2--, aliphatic, haloaliphatic, hydroxyaliphatic, aminoaliphatic, alkoxyaliphatic, alkylaminoaliphatic, alkylthioaliphatic, arylaliphatic, heterocyclylaliphatic, cycloalkylaliphatic, aryloxyaliphatic, heterocyclyloxyaliphatic, cycloalkyloxyaliphatic, arylaminoaliphatic, heterocyclylaminoaliphatic, cycloalkylaminoaliphatic, aryl, heteroaryl, heterocyclyl or carbocyclyl, with the proviso that where R.sup.5 and R.sup.5a are bonded to the same nitrogen atom, R.sup.5 and R.sup.5a, together with the nitrogen atom they are attached to, optionally form a substituted or unsubstituted 3-8 membered ring, including spiro and fused bicyclic rings; each of R.sup.6 and R.sup.6a is independently H, aliphatic, haloaliphatic, hydroxyaliphatic, aminoaliphatic, alkoxyaliphatic, alkylaminoaliphatic, alkylthioaliphatic, arylaliphatic, heterocyclylaliphatic, cycloalkylaliphatic, aryloxyaliphatic, heterocyclyloxyaliphatic, cycloalkyloxyaliphatic, arylaminoaliphatic, heterocyclylaminoaliphatic, cycloalkylaminoaliphatic, aryl, heteroaryl, heterocyclyl, or carbocyclyl; wherein each of R.sup.5aR.sup.5N--, --C(.dbd.O)NR.sup.5R.sup.5a, --OC(.dbd.O)NR.sup.5R.sup.5a, --OC(.dbd.O)OR.sup.5, --NR.sup.5C(.dbd.O)NR.sup.5R.sup.5a, --NR.sup.5C(.dbd.O)OR.sup.5a, --NR.sup.5C(.dbd.O)--R.sup.5a, R.sup.5R.sup.5N--O.sub.2S--, R.sup.5O.sub.2S--, R.sup.5O.sub.2SR.sup.5aN--, OR.sup.5, NR.sup.5, CR.sup.4R.sup.4a, CR.sup.4, (CR.sup.4R.sup.4a).sub.m, --NR.sup.5C(.dbd.O)--(CR.sup.4R.sup.4a).sub.p--, --NR.sup.5C(.dbd.S)--(CR.sup.4R.sup.4a).sub.p--, --NR.sup.5a-(CR.sup.4R.sup.4a).sub.p--, --NR.sup.5--(CR.sup.4R.sup.4a).sub.pC(.dbd.O)--, --NR.sup.5--(CR.sup.4R.sup.4a).sub.pC(.dbd.S)--, --NR.sup.5S(.dbd.O).sub.r--, --NR.sup.5S(.dbd.O)(CR.sup.4R.sup.4a).sub.p--, --C(.dbd.O)NR.sup.5--(CR.sup.4R.sup.4a).sub.p--, --NR.sup.5--(CR.sup.4R.sup.4a).sub.p--S(.dbd.O).sub.r--, R.sup.5aR.sup.5N-alkyl, R.sup.5S(.dbd.O)-alkyl, R.sup.5R.sup.5N--C(.dbd.O)-alkyl, R.sup.5aR.sup.5N-alkoxy, R.sup.5S(.dbd.O), alkoxy, R.sup.5R.sup.5N--C(.dbd.O)-alkoxy, R.sup.6R.sup.6aNC(.dbd.O)--, R.sup.6OC(.dbd.O)--, R.sup.6C(.dbd.O)--, R.sup.6R.sup.6aNS(.dbd.O)--, R.sup.6OS(.dbd.O)--, R.sup.6S(.dbd.O)--, R.sup.6R.sup.6aNSO.sub.2--, R.sup.6OSO.sub.2--, R.sup.6SO.sub.2--, hydroxy-substituted cyclopropylalkoxy, R.sup.5S(.dbd.O).sub.2O-substituted cyclopropylalkoxy, aliphatic, alkoxy, hydroxyalkoxy, aminoalkoxy, hydroxy-substituted aminoalkoxy, haloalkoxy, amino-substituted haloalkoxy, alkylamino haloalkoxy, hydroxy-substituted haloalkoxy, alkylaminoalkoxy, alkoxyalkoxy, arylalkoxy, heterocyclylalkoxy, carbocyclylalkoxy, heterocyclyl(hydroxyalkoxy), carbocyclyl(hydroxyalkoxy), aryl(hydroxyalkoxy), aryloxyalkoxy, aryloxy, heterocyclyloxyalkoxy, carbocyclyloxyalkoxy, heterocyclyloxy, cycloalkyloxy, (heterocyclo)hydroxyalkoxy, azidoalkoxy, fused bicyclyl, fused heterobicyclyl, fused bicyclyl aliphatic, fused heterobicyclyl aliphatic, fused bicycloxy, fused heterobicycloxy, fused bicyclylamino, fused heterobicyclylamino, fused bicycloxoalkoxy, fused heterobicycloxoalkoxy, fused bicyclyl aminoalkoxy, fused heterobicyclyl aminoalkoxy, fused bicyclyl-C(.dbd.O)--, fused bicyclyl-C(.dbd.O)O--, fused heterobicyclyl-C(.dbd.O)--, fused heterobicyclyl-C(.dbd.O)O--, fused bicyclylamino-C(.dbd.O)--, fused heterobicyclylamino-C(.dbd.O)--, fused bicyclyl-C(.dbd.O)NR.sup.5--, fused heterobicyclyl-C(.dbd.O)NR.sup.5--, spiro bicyclyl, spiro heterobicyclyl, spiro bicyclyl aliphatic, spiro heterobicyclyl aliphatic, spiro bicycloxy, spiro heterobicycloxy, spiro bicyclylamino, spiro heterobicyclylamino, spiro bicycloxoalkoxy, spiro heterobicycloxoalkoxy, spiro bicyclylaminoalkoxy, spiro heterobicyclylaminoalkoxy, spiro bicyclyl --C(.dbd.O)--, spiro bicyclyl-C(.dbd.O)O--, spiro heterobicyclyl-C(.dbd.O)--, spiro heterobicyclyl-C(.dbd.O)O--, spiro bicyclylamino-C(.dbd.O)--, spiro heterobicyclylamino-C(.dbd.O)--, spiro bicyclyl-C(.dbd.O)NR.sup.5--, or spiro heterobicyclyl-C(.dbd.O)NR.sup.5--, aryl, heteroaryl, arylaliphatic and heteroarylaliphatic, haloaliphatic, hydroxyaliphatic, aminoaliphatic, alkoxyaliphatic, alkylaminoaliphatic, alkylthioaliphatic, aryloxyaliphatic, heterocyclyloxyaliphatic, cycloalkyloxyaliphatic, arylaminoaliphatic, heterocyclylaminoaliphatic, cycloalkylaminoaliphatic, arylaliphatic, heterocyclylaliphatic, cycloalkylaliphatic, heterocyclyl and carbocyclyl is independently substituted or unsubstituted.

2. The compound according to claim 1, wherein R.sup.3 is independently H, F, Cl, Br, --CN, C.sub.1-3 aliphatic, C.sub.1-3 alkoxy, or C.sub.1-3 haloalkyl.

3. The compound according to claim 1, wherein Q.sub.i is ##STR00087## wherein R.sup.3a is H, F, Cl, Br, I, --CN, hydroxyl, R.sup.5aR.sup.5N--, R.sup.5aR.sup.5N-aliphatic, hydroxyaliphatic, aliphatic, alkoxy, alkoxyaliphatic, haloalkyl, heterocyclyl, heterocyclylalkyl, cycloalkyl, cycloalkoxy aliphatic, heterocycloxy aliphatic, cycloalkylalkoxy, heterocyclylalkoxy, aryloxyalkyl, heteroaryloxy aliphatic, arylaliphatic, heteroaryl aliphatic, aryl, or heteroaryl.

4. The compound according to claim 1, wherein Q.sub.2 is ##STR00088##

5. The compound according to claim 1, wherein X.sub.1 is O or NR.sup.5.

6. The compound according to claim 1, wherein Z of formula (IIa) is --NHC(.dbd.O)--, and the substructure defined by X.sub.1, U.sub.1 and R.sup.3 of Formula I is: ##STR00089##

7. The compound according to claim 1, wherein: R.sup.1 is hydroxy-substituted cyclopropyl C.sub.1-6alkoxy, R.sup.5S(.dbd.O).sub.2O-substituted cyclopropyl C.sub.1-6alkoxy, C.sub.5-12 spiro bicyclyl, C.sub.5-12 spiro heterobicyclyl, C.sub.5-12 spiro bicyclyl C.sub.1-6 aliphatic, C.sub.5-12 spiro heterobicyclyl C.sub.1-6 aliphatic, C.sub.5-12 spiro heterobicycloxo C.sub.1-6 alkoxy, C.sub.5-12 spiro heterobicyclylamino C.sub.1-6 alkoxy, C.sub.5-12 spiro bicyclyl --C(.dbd.O)--, C.sub.5-12 spiro bicyclyl-C(.dbd.O)O--, C.sub.5-12 spiro heterobicyclyl-C(.dbd.O)--, C.sub.5-12 spiro heterobicyclyl-C(.dbd.O)O--, C.sub.5-12 spiro bicyclylamino-C(.dbd.O)--, C.sub.5-12 spiro heterobicyclylamino-C(.dbd.O)--, C.sub.5-12 spiro bicyclyl-C(.dbd.O)NR.sup.5--, or C.sub.5-12 spiro heterobicyclyl-C(.dbd.O)NR.sup.5--; and R.sup.2 is H, halo, cyano(CN), R.sup.5aR.sup.5N--C.sub.1-6 alkoxy, optionally substituted C.sub.1-6 alkoxy, C.sub.1-6 hydroxyalkoxy, C.sub.1-6 aminoalkoxy, C.sub.1-6 hydroxy-substituted aminoalkoxy, C.sub.1-6 haloalkoxy, C.sub.1-6 alkylamino C.sub.1-6 alkoxy, C.sub.1-6 alkoxy C.sub.1-6 alkoxy, C.sub.4-10 heterocyclyloxy C.sub.1-6 alkoxy, C.sub.5-12 fused bicyclyl, C.sub.5-12 fused bicyclyl C.sub.1-6 aliphatic, C.sub.5-12 fused heterobicyclyl C.sub.1-6 aliphatic, C.sub.5-12 fused bicycloxy, C.sub.5-12 fused bicyclylamino, C.sub.5-12 fused bicycloxo C.sub.1-6 alkoxy, C.sub.5-12 fused bicyclylamino C.sub.1-6 alkoxy, C.sub.5-12 fused bicyclyl-C(.dbd.O)--, C.sub.5-12 fused bicyclyl-C(.dbd.O)O--, C.sub.5-12 fused heterobicyclyl-C(.dbd.O)--, C.sub.5-12 fused heterobicyclyl-C(.dbd.O)O--, C.sub.5-12 fused bicyclylamino-C(.dbd.O)--, C.sub.5-12 fused heterobicyclylamino-C(.dbd.O)--, C.sub.5-12 fused bicyclyl-C(.dbd.O)NR.sup.5--, C.sub.5-12 fused heterobicyclyl-C(.dbd.O)NR.sup.5--, C.sub.5-12 spiro bicyclyl, C.sub.5-12 spiro bicycloxy, C.sub.5-12 spiro bicyclylamino, C.sub.5-12 spiro bicycloxo C.sub.1-6 alkoxy, C.sub.5-12 spiro bicyclylamino C.sub.1-6 alkoxy, C.sub.5-12 fused heterobicyclyl, C.sub.5-12 fused heterobicycloxy, C.sub.5-12 fused heterobicyclylamino, C.sub.5-12 fused heterobicycloxo C.sub.1-6 alkoxy, C.sub.5-12 fused heterobicyclylamino C.sub.1-6 alkoxy, C.sub.5-12 spiro bicyclyl, C.sub.5-12 spiro heterobicyclyl, C.sub.5-12 spiro bicyclyl C.sub.1-6 aliphatic, C.sub.5-12 spiro heterobicyclyl C.sub.1-6 aliphatic, C.sub.5-12 spiro heterobicycloxo C.sub.1-6 alkoxy, C.sub.5-12 spiro heterobicyclylamino C.sub.1-6 alkoxy, C.sub.5-12 spiro bicyclyl --C(.dbd.O)--, C.sub.5-12 spiro bicyclyl-C(.dbd.O)O--, C.sub.5-12 spiro heterobicyclyl-C(.dbd.O)--, C.sub.5-12 spiro heterobicyclyl-C(.dbd.O)O--, C.sub.5-12 spiro bicyclylamino-C(.dbd.O)--, C.sub.5-12 spiro heterobicyclylamino-C(.dbd.O)--, C.sub.5-12 spiro bicyclyl-C(.dbd.O)NR.sup.5--, or C.sub.5-12 spiro heterobicyclyl-C(.dbd.O)NR.sup.5--, C.sub.6-10 aryl, C.sub.1-10 heteroaryl, C.sub.6-10 aryl C.sub.1-6 aliphatic or C.sub.1-10 heteroaryl C.sub.1-6 aliphatic.

8. The compound according to claim 1, wherein R.sup.1 has one of the following structures: ##STR00090## ##STR00091## ##STR00092## wherein each of X.sub.4 and X.sub.4' is independently (CR.sup.4R.sup.4a).sub.m, Me, O, S, S.dbd.O or SO.sub.2; each of m and n is independently 0, 1 or 2; and t is 1, 2 or 3.

9. The compound of claim 1 having one of the following structures: ##STR00093## ##STR00094## ##STR00095## ##STR00096## ##STR00097## or a stereoisomer, a geometric isomer, a tautomer, an N-oxide, or a pharmaceutically acceptable salt thereof.

10. A compound of Formula (IV): ##STR00098## or a stereoisomer, a geometric isomer, a tautomer, an N-oxide, or a pharmaceutically acceptable salt thereof, wherein: Q.sub.2 has formula (III): ##STR00099## R.sup.1 is one of the following structures: ##STR00100## ##STR00101## ##STR00102## wherein each of X.sub.4 and X.sub.4' is independently (CR.sup.4R.sup.4a).sub.m, NR.sup.5, O, S, S.dbd.O or SO.sub.2; each of m and n is independently 0, 1 or 2; and t is 1, 2 or 3; R.sup.2 is H, halo, cyano, hydroxyl, R.sup.5aR.sup.5N--, --C(.dbd.O)NR.sup.5R.sup.5a, --OC(.dbd.O)NR.sup.5R.sup.5a, --OC(.dbd.O)OR.sup.5, --NR.sup.5C(.dbd.O)NR.sup.5R.sup.5a, --NR.sup.5C(.dbd.O)OR.sup.5a, --NR.sup.5C(.dbd.O)--R.sup.5a, R.sup.5R.sup.5aN--O.sub.2S--, R.sup.5O.sub.2S--, R.sup.5O.sub.2SR.sup.5aN--, R.sup.5aR.sup.5N-alkyl, R.sup.5S(.dbd.O)-alkyl, R.sup.5R.sup.5aN-C(.dbd.O)-alkyl, R.sup.5aR.sup.5N-alkoxy, R.sup.5S(.dbd.O)-alkoxy, R.sup.5R.sup.5aN-C(.dbd.O)-alkoxy, aliphatic, alkoxy, hydroxyalkoxy, aminoalkoxy, hydroxy-substituted aminoalkoxy, haloalkoxy, amino-substituted haloalkoxy, alkylamino haloalkoxy, hydroxy-substituted haloalkoxy, alkylaminoalkoxy, alkoxyalkoxy, arylalkoxy, heterocyclylalkoxy, carbocyclylalkoxy, heterocyclyl(hydroxyalkoxy), carbocyclyl(hydroxyalkoxy), aryl(hydroxyalkoxy), aryloxyalkoxy, aryloxy, heterocyclyloxyalkoxy, carbocyclyloxyalkoxy, heterocyclyloxy, cycloalkyloxy, (heterocyclo)hydroxyalkoxy, azidoalkoxy, fused bicyclyl, fused heterobicyclyl, fused bicyclyl aliphatic, fused heterobicyclyl aliphatic, fused bicycloxy, fused heterobicycloxy, fused bicyclylamino, fused heterobicyclylamino, fused bicycloxoalkoxy, fused heterobicycloxoalkoxy, fused bicyclyl aminoalkoxy, fused heterobicyclyl aminoalkoxy, fused bicyclyl-C(.dbd.O)--, fused bicyclyl-C(.dbd.O)O--, fused heterobicyclyl-C(.dbd.O)--, fused heterobicyclyl-C(.dbd.O)O--, fused bicyclylamino-C(.dbd.O)--, fused heterobicyclylamino-C(.dbd.O)--, fused bicyclyl-C(.dbd.O)NR.sup.5--, fused heterobicyclyl-C(.dbd.O)NR.sup.5--, spiro bicyclyl, spiro heterobicyclyl, spiro bicyclyl aliphatic, spiro heterobicyclyl aliphatic, spiro bicycloxy, spiro heterobicycloxy, spiro bicyclylamino, spiro heterobicyclylamino, spiro bicycloxoalkoxy, spiro heterobicycloxoalkoxy, spiro bicyclylaminoalkoxy, spiro heterobicyclylaminoalkoxy, spiro bicyclyl --C(.dbd.O)--, spiro bicyclyl-C(.dbd.O)O--, spiro heterobicyclyl-C(.dbd.O)--, spiro heterobicyclyl-C(.dbd.O)O--, spiro bicyclylamino-C(.dbd.O)--, spiro heterobicyclylamino-C(.dbd.O)--, spiro bicyclyl-C(.dbd.O)NR.sup.5--, or spiro heterobicyclyl-C(.dbd.O)NR.sup.5--, aryl, heteroaryl, arylaliphatic or heteroarylaliphatic, with the proviso that when alkoxy or alkylamino is substituted, each of alkoxy or alkylamino is independently substituted with one or more hydroxy groups, amino groups or substituted amino groups; R.sup.3 is H, F, Cl, Br, I, --CN, hydroxyl, R.sup.5aR.sup.5N--, aliphatic, alkoxy, haloalkyl, heterocyclyl, heterocyclylalkyl, cycloalkyl, cycloalkyl aliphatic, cycloalkylalkoxy, or heterocyclylalkoxy; each of U.sub.1 and U.sub.2 is independently CR.sup.4 or N; V.sub.1 is O or NR.sup.5; V.sub.2 is cR.sup.4R.sup.4a, NR.sup.5, CR.sup.4 or N, and V.sub.3 and V.sub.4 combine to become CR.sup.4R.sup.4a, NR.sup.5, O, CR.sup.4 or N; each of W.sub.1, W.sub.2, W.sub.3 and W.sub.4 is independently CR.sup.4R.sup.4a, NR.sup.5, CR.sup.4 or N; X.sub.1 is (CR.sup.4R.sup.4a).sub.m, NR.sup.5, O, S, S.dbd.O or SO.sub.2, where m is 0, 1 or 2; X.sub.2 is independently O, S or NR.sup.5; Z is --NR.sup.5C(.dbd.O)--(CR.sup.4R.sup.4a).sub.p--, --NR.sup.5C(.dbd.S)--(CR.sup.4R.sup.4a).sub.p--, --NR.sup.5a--(CR.sup.4R.sup.4a).sub.p--, --NR.sup.5--(CR.sup.4R.sup.4a).sub.pC(.dbd.O)--, --NR.sup.5--(CR.sup.4R.sup.4a).sub.pC(.dbd.S)--, --NR.sup.5S(.dbd.O).sub.r--, --NR.sup.5S(.dbd.O).sub.r(CR.sup.4R.sup.4a).sub.p--, --C(.dbd.O)NR.sup.5(CR.sup.4R.sup.4a).sub.p-- or --NR.sup.5(CR.sup.4R.sup.4a).sub.pS(.dbd.O).sub.r--, where p is 0, 1, 2 or 3; and r is 1 or 2; each of R.sup.4 and R.sup.4a is independently H, F, Cl, Br, I, --CN, hydroxyl, --NR.sup.5aR.sup.5, alkoxy, cycloalkoxy, heterocycloalkoxy, aliphatic, haloaliphatic, hydroxyaliphatic, aminoaliphatic, alkoxyaliphatic, alkylaminoaliphatic, alkylthioaliphatic, aryloxyaliphatic, heterocyclyloxyaliphatic, cycloalkyloxyaliphatic, arylaminoaliphatic, heterocyclylaminoaliphatic, cycloalkylaminoaliphatic, arylaliphatic, heterocyclylaliphatic, cycloalkylaliphatic, aryl, heteroaryl, heterocyclyl or carbocyclyl, with the proviso that where R.sup.4 and R.sup.4a are bonded to the same carbon atom, R.sup.4 and R.sup.4a, together with the carbon atom they are attached to, optionally form a substituted or unsubstituted 3-8 membered carbocyclic or heterocyclic ring; each of R.sup.5 and R.sup.5a is independently H, R.sup.6R.sup.6aNC(.dbd.O)--, R.sup.6OC(.dbd.O)--, R.sup.6C(.dbd.O)--, R.sup.6R.sup.6aNS(.dbd.O)--, R.sup.6OS(.dbd.O)--, R.sup.6S(.dbd.O)--, R.sup.6R.sup.6aNSO.sub.2--, R.sup.6OSO.sub.2--, R.sup.6SO.sub.2--, aliphatic, haloaliphatic, hydroxyaliphatic, aminoaliphatic, alkoxyaliphatic, alkylaminoaliphatic, alkylthioaliphatic, arylaliphatic, heterocyclylaliphatic, cycloalkylaliphatic, aryloxyaliphatic, heterocyclyloxyaliphatic, cycloalkyloxyaliphatic, arylaminoaliphatic, heterocyclylaminoaliphatic, cycloalkylaminoaliphatic, aryl, heteroaryl, heterocyclyl or carbocyclyl, with the proviso that where R.sup.5 and R.sup.5a are bonded to the same nitrogen atom, R.sup.5 and R.sup.5a, together with the nitrogen atom they are attached to, optionally form a substituted or unsubstituted 3-8 membered ring, including spiro and fused bicyclic rings; each of R.sup.6 and R.sup.6a is independently H, aliphatic, haloaliphatic, hydroxyaliphatic, aminoaliphatic, alkoxyaliphatic, alkylaminoaliphatic, alkylthioaliphatic, arylaliphatic, heterocyclylaliphatic, cycloalkylaliphatic, aryloxyaliphatic, heterocyclyloxyaliphatic, cycloalkyloxyaliphatic, arylaminoaliphatic, heterocyclylaminoaliphatic, cycloalkylaminoaliphatic, aryl, heteroaryl, heterocyclyl, or carbocyclyl; wherein each of R.sup.5aR.sup.5N--, --C(.dbd.O)NR.sup.5R.sup.5a, --OC(.dbd.O)NR.sup.5R.sup.5a, --OC(.dbd.O)OR.sup.5, --NR.sup.5C(.dbd.O)NR.sup.5R.sup.5a, --NR.sup.5C(.dbd.O)OR.sup.5a, --NR.sup.5C(.dbd.O)--R.sup.5a, R.sup.5R.sup.5aN-O.sub.2S--, R.sup.5O.sub.2S--, R.sup.5O.sub.2SR.sup.5aN--, OR.sup.5, NR.sup.5, CR.sup.4R.sup.4a, CR.sup.4, (CR.sup.4R.sup.4a).sub.m, --NR.sup.5C(.dbd.O)--(CR.sup.4R.sup.4a).sub.p--, --NR.sup.5C(.dbd.S)--(CR.sup.4R.sup.4a).sub.p--, --NR.sup.5a-(CR.sup.4R.sup.4a).sub.p--, --NR.sup.5--(CR.sup.4R.sup.4a).sub.pC(.dbd.O)--, --NR.sup.5--(CR.sup.4R.sup.4a).sub.pC(.dbd.S)--, --NR.sup.5S(.dbd.O).sub.r--, --NR.sup.5S(.dbd.O)(CR.sup.4R.sup.4a).sub.p--, --C(.dbd.O)NR.sup.5--(CR.sup.4R.sup.4a).sub.p--, --NR.sup.5--(CR.sup.4R.sup.4a).sub.p--S(.dbd.O).sub.r--, R.sup.5aR.sup.5N-alkyl, R.sup.5(S.dbd.O)-alkyl, R.sup.5R.sup.5aN--(C.dbd.O)-alkyl, R.sup.5aR.sup.5N-alkoxy, R.sup.5(S.dbd.O)-alkoxy, R.sup.5R.sup.5N--(C.dbd.O)-alkoxy, R.sup.6R.sup.6aNC(.dbd.O)--, R.sup.6OC(.dbd.O)--, R.sup.6C(.dbd.O)--, R.sup.6R.sup.6aNS(.dbd.O)--, R.sup.6OS(.dbd.O)--, R.sup.6S(.dbd.O)--, R.sup.6R.sup.6aNSO.sub.2--, R.sup.6OSO.sub.2--, R.sup.6SO.sub.2--, hydroxy-substituted cyclopropylalkoxy, R.sup.5S(.dbd.O).sub.2O-substituted cyclopropylalkoxy, aliphatic, alkoxy, hydroxyalkoxy, aminoalkoxy, hydroxy-substituted aminoalkoxy, haloalkoxy, amino-substituted haloalkoxy, alkylamino haloalkoxy, hydroxy-substituted haloalkoxy, alkylaminoalkoxy, alkoxyalkoxy, arylalkoxy, heterocyclylalkoxy, carbocyclylalkoxy, heterocyclyl(hydroxyalkoxy), carbocyclyl(hydroxyalkoxy), aryl(hydroxyalkoxy), aryloxyalkoxy, aryloxy, heterocyclyloxyalkoxy, carbocyclyloxyalkoxy, heterocyclyloxy, cycloalkyloxy, (heterocyclo)hydroxyalkoxy, azidoalkoxy, fused bicyclyl, fused heterobicyclyl, fused bicyclyl aliphatic, fused heterobicyclyl aliphatic, fused bicycloxy, fused heterobicycloxy, fused bicyclylamino, fused heterobicyclylamino, fused bicycloxoalkoxy, fused heterobicycloxoalkoxy, fused bicyclyl aminoalkoxy, fused heterobicyclyl aminoalkoxy, fused bicyclyl-C(.dbd.O)--, fused bicyclyl-C(.dbd.O)O--, fused heterobicyclyl-C(.dbd.O)--, fused heterobicyclyl-C(.dbd.O)O--, fused bicyclylamino-C(.dbd.O)--, fused heterobicyclylamino-C(.dbd.O)--, fused bicyclyl-C(.dbd.O)NR.sup.5--, fused heterobicyclyl-C(.dbd.O)NR.sup.5--, spiro bicyclyl, spiro heterobicyclyl, spiro bicyclyl aliphatic, spiro heterobicyclyl aliphatic, spiro bicycloxy, spiro heterobicycloxy, spiro bicyclylamino, spiro heterobicyclylamino, spiro bicycloxoalkoxy, spiro heterobicycloxoalkoxy, spiro bicyclylaminoalkoxy, spiro heterobicyclylaminoalkoxy, spiro bicyclyl --C(.dbd.O)--, spiro bicyclyl-C(.dbd.O)O--, spiro heterobicyclyl-C(.dbd.O)--, spiro heterobicyclyl-C(.dbd.O)O--, spiro bicyclylamino-C(.dbd.O)--, spiro heterobicyclylamino-C(.dbd.O)--, spiro bicyclyl-C(.dbd.O)NR.sup.5--, or spiro heterobicyclyl-C(.dbd.O)NR.sup.5--, aryl, heteroaryl, arylaliphatic and heteroarylaliphatic, haloaliphatic, hydroxyaliphatic, aminoaliphatic, alkoxyaliphatic, alkylaminoaliphatic, alkylthioaliphatic, aryloxyaliphatic, heterocyclyloxyaliphatic, cycloalkyloxyaliphatic, arylaminoaliphatic, heterocyclylaminoaliphatic, cycloalkylaminoaliphatic, arylaliphatic, heterocyclylaliphatic, cycloalkylaliphatic, heterocyclyl and carbocyclyl is independently substituted or unsubstituted.

11. The compound according to claim 10, wherein R.sup.3 is independently H, F, Cl, Br, --CN, C.sub.1-3 aliphatic, C.sub.1-3 alkoxy, or C.sub.1-3 haloalkyl.

12. The compound according to claim 10, wherein the substructure defined by X.sub.2, V.sub.1, V.sub.2, V.sub.3, V.sub.4 and Z of Formula (IV) is ##STR00103## wherein R.sup.3a is H, F, Cl, Br, I, --CN, hydroxyl, R.sup.5aR.sup.5N--, R.sup.5aR.sup.5N-aliphatic, hydroxyaliphatic, aliphatic, alkoxy, alkoxyaliphatic, haloalkyl, heterocyclyl, heterocyclylalkyl, cycloalkyl, cycloalkoxy aliphatic, heterocycloxy aliphatic, cycloalkylalkoxy, heterocyclylalkoxy, aryloxyalkyl, heteroaryloxy aliphatic, arylaliphatic, heteroaryl aliphatic, aryl, or heteroaryl.

13. The compound according to claim 10 wherein Q.sub.2 is ##STR00104##

14. The compound according to claim 10, wherein X.sub.1 is O or NR.sup.5.

15. The compound according to claim 10, wherein Z is --NHC(.dbd.O)--.

16. The compound according to claim 10, wherein the substructure defined by X.sub.i, Z, U.sub.1 and R.sup.3 is ##STR00105##

17. The compound according to claim 1, wherein the substructure defined by X.sub.1, Z, U.sub.1 and R.sup.3 of Formula (IV) is: ##STR00106## the substructure defined by X.sub.2, V.sub.1, V.sub.2, V.sub.3, V.sub.4 and Z of Formula (IV) is: ##STR00107## ##STR00108## Q.sub.2 is ##STR00109## R.sup.1 is wherein each of X.sub.4 and X.sub.4' is independently O, and t is 3; R.sup.2 is H; R.sup.3a is aliphatic; and each of R.sup.5 and R.sup.5a is independently H, aliphatic or aryl.

18. The compound of claim 10 having one of the following structures: or a stereoisomer, a geometric isomer, a tautomer, an N-oxide, or a pharmaceutically acceptable salt thereof.

19. A pharmaceutical composition comprising a compound according to claim 1 and a pharmaceutically acceptable carrier, excipient, diluent, adjuvant, vehicle or a combination thereof.

20. The composition according to claim 19 further comprising a therapeutic agent selected from a chemotherapeutic agent, an anti-proliferative agent, an agent for treating atherosclerosis, an agent for treating lung fibrosis, and combinations thereof.

21. The composition according to claim 20, wherein the additional therapeutic agent is adriamycin, rapamycin, temsirolimus, everolimus, ixabepilone, gemcitabin, cyclophosphamide, dexamethasone, etoposide, fluorouracil, imatinib mesylate, dasatinib, nilotinib, erlotinib, lapatinib, iressa, sorafenib, sunitinib, an interferon, carboplatin, topotecan, taxol, vinblastine, vincristine, temozolomide, tositumomab, trabecdectin, bevacizumab, panitumumab, or a combination thereof.

Details for Patent 8,426,585

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Genentech AVASTIN bevacizumab VIAL; INTRAVENOUS 125085 001 2004-02-26   Start Trial Xi; Ning (Newbury Park, CA) Sunshine Lake Pharma Co., Ltd. (Northern Industrial Area, Songshan Lake, Dongguan, Guangdong, CN) 2028-10-14 RX Orphan search
Genentech AVASTIN bevacizumab VIAL; INTRAVENOUS 125085 002 2004-02-26   Start Trial Xi; Ning (Newbury Park, CA) Sunshine Lake Pharma Co., Ltd. (Northern Industrial Area, Songshan Lake, Dongguan, Guangdong, CN) 2028-10-14 RX Orphan search
Amgen VECTIBIX panitumumab INJECTABLE; IV (INFUSION) 125147 001 2006-09-27   Start Trial Xi; Ning (Newbury Park, CA) Sunshine Lake Pharma Co., Ltd. (Northern Industrial Area, Songshan Lake, Dongguan, Guangdong, CN) 2028-10-14 RX search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Medtronic
Harvard Business School
Moodys
Colorcon
Mallinckrodt
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.